Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors Meeting Abstract


Authors: Kelley, R. K.; Van Cutsem, E.; Lee, M. S.; Wolf, I.; Fakih, M.; de Vos-Geelen, J.; Lee, V.; Vogel, A.; Wu, X. L.; Jin, F.; Naik, G. S.; O'Reilly, E. M.
Abstract Title: Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors
Meeting Title: 2022 ASCO Gastrointestinal Cancers Symposium
Journal Title: Journal of Clinical Oncology
Volume: 40
Issue: 4 Suppl.
Meeting Dates: 2022 Jan 20-22
Meeting Location: San Francisco, CA
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2022-02-01
Language: English
ACCESSION: WOS:000770995900652
DOI: 10.1200/JCO.2022.40.4_suppl.TPS669
PROVIDER: wos
Notes: Meeting Abstract: TPS669 -- Meeting was conducted online as well as in person -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Eileen O'Reilly
    780 O'Reilly